VLST expands into oncology with clinical-stage Pfizer antibody
This article was originally published in Scrip
Executive Summary
The private US biotechnology firm VLST has added oncology to its list of targeted disease areas, on top of autoimmune and inflammatory disorders, by in-licensing the anti-CD40 monoclonal antibody CP-870,893 from Pfizer, which has taken a 5% equity position in VLST and is entitled to milestone payments from the development programme.